2023-11-13T10:02:23-06:00 2023-06-30 366055558 GRANT THORNTON LLP 1000 WILSON BOULEVARD SUITE 1500 ARLINGTON VA 22209 990 2022-07-01 131656692 UNITED STATES PHARMACOPEIAL CONVENTION UNIT 3018810666 12601 TWINBROOK PARKWAY ROCKVILLE MD 20852 STANLEY D BURHANS CHIEF FINANCIAL OFFICER 3018810666 2023-11-13 1 STANLEY BURHANS 999009999 0 MARY TORRETTA P00847851 7038477500 2 AAL1 IAL1 2022 2023-04-26 12:10:37Z RONALD T PIERVINCENZI 12601 TWINBROOK PARKWAY ROCKVILLE MD 20852 554482992 0 X WWW.USP.ORG X 1820 MD TO IMPROVE THE HEALTH OF PEOPLE AROUND THE WORLD THROUGH PUBLIC STANDARDS AND (SEE SCHEDULE O) RELATED PROGRAMS THAT HELP ENSURE THE QUALITY, SAFETY, AND BENEFIT OF MEDICINES AND FOODS. 13 13 936 671 0 0 23282824 30105843 303193655 305130377 15642447 10363719 215450 671591 342334376 346271530 1147975 838069 0 0 150485140 167844913 0 0 893766 138866555 144597630 290499670 313280612 51834706 32990918 655709010 701768432 194261946 190873220 461447064 510895212 X USP'S MISSION IS TO IMPROVE GLOBAL HEALTH THROUGH PUBLIC STANDARDS AND RELATED PROGRAMS THAT HELP ENSURE THE QUALITY, SAFETY, AND BENEFIT OF MEDICINES AND FOODS. 0 0 175189577 294781185 SEE SCHEDULE O 6802196 838069 6175722 SEE SCHEDULE O 35961423 4173470 SEE SCHEDULE O 217953196 1 1 0 1 0 0 0 0 0 0 1 1 0 1 1 1 0 1 0 1 1 1 1 0 0 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 X 174 0 1 936 1 0 1 BR CH ET GH IN RP SN SZ CA UK LU BG KE LI NP RW NI PK 0 0 0 0 0 0 0 0 0 0 X 13 13 0 0 0 0 1 1 1 1 1 0 0 1 1 1 1 1 1 1 1 0 MD X STANLEY D BURHANS 3019986781 12601 TWINBROOK PARKWAY ROCKVILLE MD 20852 DENNIS E DOHERTY MD CONVENTION PRESIDENT 4.00 0.00 X X 0 0 0 TODD K ABRAHAM PHD MBA TREASURER 4.00 0.00 X X 0 0 0 GREGORY E AMIDON PHD PHARMACEUTICAL SCIENCES TRUSTEE 4.00 0.00 X 0 0 0 GWEN DARIEN PUBLIC TRUSTEE 4.00 0.00 X 0 0 0 RICHARD J GILFILLAN MD MBA AT LARGE TRUSTEE 4.00 0.00 X 0 0 0 JESSE L GOODMAN MD MPH MEDICAL SCIENCES TRUSTEE 4.00 0.00 X 0 0 0 LAURA HERMAN MBA MA AT LARGE TRUSTEE 4.00 0.00 X 0 0 0 THOMAS MENIGHAN BSPHARMMBA AT LARGE TRUSTEE 4.00 0.00 X 0 0 0 KRISHNA REDDY NALLAMALLA MD AT LARGE TRUSTEE 4.00 0.00 X 0 0 0 STEPHEN OSTROFF MD MEDICAL SCIENCES TRUSTEE 4.00 0.00 X 0 0 0 JULIO SANCHEZ Y TEPOZ MSCSJD AT LARGE TRUSTEE 4.00 0.00 X 0 0 0 JOHN TAYLOR JD AT LARGE TRUSTEE 4.00 0.00 X 0 0 0 SUSAN WINCKLER RPH JD CHAIR AND PHARMA SCI TRUST 4.00 0.00 X 0 0 0 RONALD T PIERVINCENZI CHIEF EXECUTIVE OFFICER & EX-OFFICIO 38.00 0.00 X 898347 0 101702 JAKOB VENEMA EVP & CHIEF SCIENCE OFFICER 38.00 0.00 X 549453 0 66721 AMANDA D COWLEY SVP LEGAL PEOPLE STRATEGY 38.00 0.00 X 465868 0 57967 ANTHONY P LAKAVAGE SECRETARY & SVP GLBL EA 38.00 0.00 X 463649 0 56571 STANLEY D BURHANS CHIEF FINANCIAL OFFICER 38.00 0.00 X 446383 0 55805 EMILY M KAINE SVP, GHMS 38.00 0.00 X 465653 0 53168 VENKAT SURENDRA NATH KODURU SVP REGIONS & PROGRAM OPS. 38.00 0.00 X 450579 0 9091 BRUK ALEMAYEHU SVP, GLTO 38.00 0.00 X 372277 0 49170 JENNIFER DEVINE SVP, DOC STDS & COMP POLICY 38.00 0.00 X 367442 0 36514 DAWN M ORAM HEAD OF GPC (THRU DEC 2022) 38.00 0.00 X 352426 0 39776 MICHAEL S LEVY SVP, DIGITAL & INNOVATION 38.00 0.00 X 350728 0 43223 FOUAD ATOUF SVP, SCI-GLOB BIO 38.00 0.00 X 350495 0 50220 ROBERT L ANDERSON VP, MKTG COMMS EXEC 38.00 0.00 X 326364 0 33811 5859664 0 653739 604 0 1 0 VELOCITY GLOBAL LLC 3858 WALNUT ST STE 107 DENVER CO 80205 CONSULTING 2152369 SMART SYNERGIES 20130 LAKEVIEW CENTER PLAZA ASHBURN VA 20147 IT SERVICES 1806686 EMCOR SERVICES CES INC 2800 CRYSTAL DR STE 600 ARLINGTON VA 22202 FACILITIES SERVICES 1735562 BELL TECHLOGIX INC 4400 WEST 96TH INDIANAPOLIS IN 46268 IT SERVICES 1601727 ERNST & YOUNG LLP 5 TIMES SQUARE NEW YORK CITY NY 10036 CONSULTING 1329690 77 28296837 1809006 1809006 30105843 COMPENDIAL ACTIVITIES 423490 294781185 294781185 ALLIED COMPENDIAL ACT. 423490 6175722 6175722 NON-COMPENDIAL ACT. 423490 4173470 4173470 305130377 9877318 9877318 234034 234034 208697863 208024051 187411 673812 -187411 486401 486401 INSURANCE PROCEEDS 900099 437557 437557 437557 346271530 305130377 0 11035310 X 289086 289086 445000 445000 103983 103983 4558851 2047578 2412588 98685 132662776 97202678 34858687 601411 11615302 8401166 3154875 59261 10256651 7418475 2785847 52329 8751333 6329702 2376982 44649 757018 757018 445141 445141 228200 228200 819834 819834 35383345 23106184 12277161 1105912 1104658 1254 6989419 6418966 569869 584 14266601 3081608 11184993 7890578 2349190 5541388 4572942 4076287 464709 31946 2445409 2084827 357853 2729 3254882 3254882 31503841 30020084 1483757 11714791 5076957 6637834 1244651 1244651 COST OF GOODS SOLD 10098926 10098926 VALIDATION &CALIBRATION 3705686 3163665 542021 BANK & CREDIT CARD FEES 2712464 2712464 PUB/SUBSCRIPTIONS 1842212 1798699 43163 350 3615778 3335477 278479 1822 313280612 217953196 94433650 893766 22240432 26386133 24991484 29791627 3878781 5771450 45216659 42283399 61476483 65915852 11196460 11594049 246371456 115908741 134090207 130462715 231710693 268930059 56251745 65322012 64656066 55311136 655709010 701768432 63190068 66136200 6489083 6411400 95536011 91861224 29046784 26464396 194261946 190873220 X 461447064 510895212 461447064 510895212 655709010 701768432 X 32990918 18817027 -2359797 X 0 1 X 1 1 1 X 15062188 9078335 12769050 23282824 30105843 90298240 312071879 305245294 303225858 303193655 305130377 1528867063 327134067 314323629 315994908 326476479 335236220 1619165303 0 0 0 1619165303 5796509 5989995 4069196 9158226 10111352 35125278 5796509 5989995 4069196 9158226 10111352 35125278 225187 -100581 78336 437557 640499 333155763 320213043 320064104 335713041 345785129 1654931080 0.97840 0.98230 0.02120 0.01730 X SCHEDULE A, PART III, LINE 12, EXPLANATION OF OTHER INCOME: OTHER INCOME - 2018 AMOUNT: $ 225,187. 2019 AMOUNT: $ -100,581. 2020 AMOUNT: $ 0. 2021 AMOUNT: $ 78,336. 2022 AMOUNT: $ 437,557. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 228200 228200 313052412 313280612 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 471698 384899 369423 228200 1454220 250000 250000 250000 250000 1000000 1500000 SCHEDULE C, PART II-A USP ENGAGES WITH PAID LOBBYISTS TO SECURE GOVERNMENTAL FUNDING WHICH IS THEN USED TO FURTHER USP'S TAX-EXEMPT MISSION. 9389846 9389846 136666276 48801678 87864598 21535219 8504576 13030643 45133753 33736541 11397212 33646362 24865946 8780416 130462715 ALTERNATIVE INVESTMENTS 65322012 F 65322012 INVESTMENT IN FOREIGN SUBS. 29840678 RIGHT OF USE (LEASE) ASSET 16774933 DUE FROM PHARMATECH 4000000 457(B) PLAN ASSETS 3775000 DEPOSITS 920525 55311136 LEASE LIABILITIES 26023908 OTHER LONG-TERM LIABILITIES 440488 26464396 X PART X, LINE 2: USPC FOLLOWS GUIDANCE THAT CLARIFIES THE ACCOUNTING FOR UNCERTAINTY IN TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN, INCLUDING ISSUES RELATING TO CONSOLIDATED FINANCIAL STATEMENT RECOGNITION AND MEASUREMENT. THIS GUIDANCE PROVIDES THAT THE TAX EFFECTS FROM AN UNCERTAIN TAX POSITION CAN ONLY BE RECOGNIZED IN THE CONSOLIDATED FINANCIAL STATEMENTS IF THE POSITION IS "MORE-LIKELY-THAN-NOT" TO BE SUSTAINED IF THE POSITION WERE TO BE CHALLENGED BY A TAXING AUTHORITY. THE ASSESSMENT OF THE TAX POSITION IS BASED SOLELY ON THE TECHNICAL MERITS OF THE POSITION, WITHOUT REGARD TO THE LIKELIHOOD THAT THE TAX POSITION MAY BE CHALLENGED. 1 SOUTH ASIA 1 344 PROGRAM SERVICES COMPENDIAL 14667311 EAST ASIA AND THE PACIFIC 1 5 PROGRAM SERVICES SALES OFFICE 1138209 SUB-SAHARAN AFRICA 1 33 PROGRAM SERVICES PQM OFFICE/USAID 3130578 EAST ASIA AND THE PACIFIC 1 14 PROGRAM SERVICES PQM OFFICE/USAID 726535 SOUTH ASIA 1 25 PROGRAM SERVICES PQM OFFICE/USAID 1508330 SUB-SAHARAN AFRICA 1 22 PROGRAM SERVICES COMPENDIAL 1975894 SOUTH AMERICA 1 12 PROGRAM SERVICES COMPENDIAL 2202622 EUROPE (INCLUDING ICELAND & GREENLAND) 1 7 PROGRAM SERVICES SALES OFFICE 2468249 EAST ASIA AND THE PACIFIC 1 24 PROGRAM SERVICES COMPENDIAL 4316270 SUB-SAHARAN AFRICA INVESTMENTS 744587 EUROPE (INCLUDING ICELAND & GREENLAND) INVESTMENTS 1227538 SOUTH AMERICA INVESTMENTS 2836592 EAST ASIA AND THE PACIFIC INVESTMENTS 3151243 SOUTH ASIA INVESTMENTS 13591272 SUB-SAHARAN AFRICA GRANTMAKING 70144 EUROPE (INCLUDING ICELAND & GREENLAND) GRANTMAKING 33839 8 462 1 24 9 486 27817728 25971485 53789213 EUROPE (INCLUDING ICELAND & GREENLAND) WORLD VACCINE CONGRESS 2023 - GOLD SPONSORSHIP 30000 WIRE TRANSFER 0 1 USP GLOBAL FELLOWSHIP PROGRAM SUB-SAHARAN AFRICA 1 70144 1 0 1 0 0 1 PART I, LINE 2: PROCEDURES FOR MONITORING THE USE OF GRANTS OUTSIDE U.S. USP WILL ESTABLISH A SPECIFIC REPORTING PROCESS AND TIMING WITH EACH FOREIGN ORGANIZATION AND INDIVIDUAL WHO RECEIVES A GRANT. THE REPORTING METHODOLOGY AND TIMING OF THE REPORTS WILL CARRY ON A PER GRANT BASIS. AT A MINIMUM, THE GRANTEE WILL BE EXPECTED TO PROVIDE A NARRATIVE STATEMENT AS TO THE PROGRESS MADE IN ACCOMPLISHING THE PURPOSE OF THE GRANT. PART I, LINE 3: ACCOUNTING METHOD USED THE EXPENDITURES, PER REGION, ARE PRESENTED ON THE ACCRUAL BASIS OF ACCOUNTING. PART III ACCOUNTING METHOD: 1 ASSOCIATION FOR ACCESSIBLE MEDICINES 601 NEW JERSEY AVE NW STE 850 WASHINGTON DC 20001 522252820 501(C)(6) 80000 0 2023 GRX AND AAM ACCESS! SPONSORSHIPS ARTHRITIS FOUNDATION INC 1355 PEACHTREE ST STE 600 ATLANTA GA 30309 874004425 501(C)(3) 37502 0 ARTHRITIS HEALTHCARE FORUM SPONSORSHIP NEWARK MENTORING MOVEMENT 60 PARK PLACE NEWARK NJ 07102 131624107 501(C)(3) 25000 0 NEWARK MENTORING MOVEMENT - CAPACITY BUILDER SPONSOR PANIC NMR ASSOCIATION INC 520 LAMPLIGHTER WAY LANSDALE PA 19446 475577736 501(C)(3) 22160 0 RESONATOR SPONSORSHIP - USP QNMR SESSION IN PANIC AMERICAN PHARMACISTS ASSOCIATION (APHA) 2215 CONSTITUTION AVE NW WASHINGTON DC 200372985 526039142 501(C)(3) 21800 0 APHA2022 PAST LEADERSHIP LUNCHEON DUKE UNIVERSITY BOX 90759 DURHAM NC 277081020 560532129 501(C)(3) 20000 0 DUKE UNIVERSITY DONATION REAGAN UDALL FOUNDATION FOR THE FOOD AND DRUG ADMINISTRATION INC 1900 L ST NW WASHINGTON DC 20036 530214882 501(C)(3) 15000 0 USP'S 2022 INNOVATIONS IN REG SCIENCE SPONSORSHIP NATIONAL ASSOCIATION OF BOARDS OF PHARMACY 1600 FEEHANVILLE DRIVE MOUNT PROSPECT IL 600566014 361520565 501(C)(3) 12000 0 2023 NABP ANNUAL MEETING SPONSORSHIP AMERICAN CANCER SOCIETY PO BOX 22718 OKLAHOMA CITY OK 731231718 455092471 501(C)(3) 10000 0 ACS CAN 2023 CORPORATE MEMBERSHIP ALLIANCE FOR AGING RESEARCH 1700 K ST NW STE 740 WASHINGTON DC 20006 541379174 501(C)(3) 10000 0 ANNUAL DINNER SPONSORSHIP-BRONZE NATIONAL HEALTH COUNCIL INC 1730 M ST NW WASHINGTON DC 20036 263727917 501(C)(3) 8000 0 NATIONAL HEALTH COUNCIL 2023 DUES C&O CANAL TRUST INC 142 W POTOMAC ST HAGERSTOWN MD 21740 300401642 501(C)(3) 6600 0 C&O CANAL SPONSORSHIP 11 1 USP GLOBAL FELLOWSHIP PROGRAM 4 445000 PART I, LINE 2: PROCEDURE FOR MONITORING USE OF GRANT FUNDS INSIDE U.S. USP HAS ESTABLISHED A SPECIFIC REPORTING PROCESS AND TIMING WITH EACH INDIVIDUAL GRANT RECIPIENT. THE REPORTING METHODOLOGY AND TIMING OF THE REPORTS WILL VARY ON A PER GRANT BASIS. AT A MINIMUM, THE GRANTEE WILL BE EXPECTED TO PROVIDE A NARRATIVE STATEMENT AS TO THE PROGRESS MADE IN ACCOMPLISHING THE PURPOSE OF THE GRANT. ORGANIZATIONS RECEIVING MONETARY SUPPORT FROM USP IN THE FORM OF SPONSORSHIP PROVIDE USP WITH ACKNOWLEDGEMENT OF THE RECEIPT AND CONFIRMATION THAT THE USES OF THE FUNDS PROVIDED WERE FOR THE STATED AND AGREED TO PURPOSE. X X X X 0 1 0 0 0 0 0 1 0 RONALD T PIERVINCENZI CHIEF EXECUTIVE OFFICER & EX-OFFICIO 726777 0 169153 0 2417 0 90694 0 11008 0 1000049 0 0 0 JAKOB VENEMA EVP & CHIEF SCIENCE OFFICER 469769 0 76362 0 3322 0 55714 0 11007 0 616174 0 0 0 AMANDA D COWLEY SVP LEGAL PEOPLE STRATEGY 387450 0 75088 0 3330 0 47457 0 10510 0 523835 0 0 0 ANTHONY P LAKAVAGE SECRETARY & SVP GLBL EA 386109 0 74373 0 3167 0 47005 0 9566 0 520220 0 0 0 EMILY M KAINE SVP, GHMS 389512 0 74373 0 1768 0 47005 0 6163 0 518821 0 0 0 STANLEY D BURHANS CHIEF FINANCIAL OFFICER 381038 0 62178 0 3167 0 45366 0 10439 0 502188 0 0 0 VENKAT SURENDRA NATH KODURU SVP REGIONS & PROGRAM OPS. 375435 0 59894 0 15250 0 7427 0 1664 0 459670 0 0 0 BRUK ALEMAYEHU SVP, GLTO 314425 0 51886 0 5966 0 37856 0 11314 0 421447 0 0 0 JENNIFER DEVINE SVP, DOC STDS & COMP POLICY 314403 0 49949 0 3090 0 36442 0 72 0 403956 0 0 0 FOUAD ATOUF SVP, SCI-GLOB BIO 281934 0 65560 0 3001 0 36156 0 14064 0 400715 0 0 0 MICHAEL S LEVY SVP, DIGITAL & INNOVATION 291457 0 56428 0 2843 0 35663 0 7560 0 393951 0 0 0 DAWN M ORAM HEAD OF GPC (THRU DEC 2022) 229956 0 119233 0 3237 0 34029 0 5747 0 392202 0 0 0 ROBERT L ANDERSON VP, MKTG COMMS EXEC 277810 0 44504 0 4050 0 32470 0 1341 0 360175 0 0 0 SCHEDULE J, PART I, LINE 4B: SUPPLEMENTAL NONQUALIFIED RETIREMENT PLAN DURING THE YEAR, CERTAIN INDIVIDUALS PARTICIPATED IN A SUPPLEMENTAL NONQUALIFIED RETIREMENT PLAN. NONE OF THE INDIVIDUALS LISTED ON SCHEDULE J, PART II RECEIVED TAXABLE PAYMENTS IN THE CURRENT YEAR. THE FOLLOWING INDIVIDUALS RECEIVED DEFERRED CONTRIBUTIONS (UNPAID AND ELIGIBLE FOR PAYMENT BASED ON VESTING AND PAYOUT SCHEDULE) REPORTED ON SCHEDULE J, PART II, COLUMN C, RETIREMENT AND OTHER DEFERRED COMPENSATION: RONALD T. PIERVINCENZI: $60,194 JAKOB VENEMA: $25,214 AMANDA D. COWLEY: $16,957 EMILY M. KAINE: $16,505 ANTHONY LAKAVAGE: $16,505 STANLEY D. BURHANS: $14,866 BRUK ALEMAYEHU: $7,356 JENNIFER DEVINE: $5,942 FOUAD ATOUF: $5,656 MICHAEL S. LEVY: $5,163 ROBERT L. ANDERSON: $1,970 SCHEDULE J, PART I, LINE 7: NON-FIXED PAYMENTS USP PROVIDES INCENTIVE COMPENSATION THAT IS COMMENSURATE WITH THE ACCOMPLISHMENT OF STATED GOALS. EACH INDIVIDUAL OFFICER, KEY EMPLOYEE, OR HIGHLY COMPENSATED EMPLOYEE HAS AN ANNUAL GOAL PLAN. BASED ON THE ACCOMPLISHMENT OF THOSE INDIVIDUAL STATED GOALS, THE INDIVIDUAL IS ELIGIBLE FOR A BONUS WHICH IS WITHIN A FIXED PERCENTAGE RANGE. BONUSES ARE CONSIDERED AS PART OF THE TOTAL COMPENSATION WHEN DETERMINING REASONABLENESS. A MARYLAND ECONOMIC DEVELOPMENT CORPORATION 521376562 000000000 2012-03-29 109360000 REFUND OF '08 & '09 TX-EX BONDS 0 0 0 A 17185000 109360000 4524 109355476 1 0 1 1 A 0 0 0 0 0 0 1 A 0 0 1 0 0 0 0 0 1 A 1 X RAW MATERIALS 152 1809006 REPLACEMENT COST 0 1 0 SCHEDULE M, PART I, COLUMN (B): NUMBER OF CONTRIBUTIONS THE NUMBERS LISTED IN PART I, COLUMN B, REFLECT THE NUMBER OF INDIVIDUAL CONTRIBUTIONS RECEIVED. FORM 990, PART III, LINE 4A: PROGRAM SERVICE ACCOMPLISHMENTS COMPENDIAL PROGRAMS - USP ESTABLISHES INTERNATIONALLY RECOGNIZED PUBLIC STANDARDS (BOTH DOCUMENTARY STANDARDS AND THE PHYSICAL REFERENCE MATERIALS THAT SUPPORT THE APPLICATION AND USE OF THESE DOCUMENTARY STANDARDS) TO HELP ENSURE GOOD QUALITY MEDICINES, DIETARY SUPPLEMENTS, FOOD INGREDIENTS, AND RELATED PRODUCTS USED TO MAINTAIN HEALTH AND TREAT DISEASE. THESE STANDARDS ARE DEVELOPED USING AN OPEN, PUBLIC PROCESS AND ARE APPROVED BY INDEPENDENT SCIENTIFIC EXPERTS. PRESCRIPTION AND OVER THE COUNTER MEDICINES AVAILABLE IN THE UNITED STATES MUST, BY FEDERAL LAW, MEET USP'S PUBLIC STANDARDS, WHERE SUCH STANDARDS EXIST. MANY OTHER COUNTRIES REQUIRE THE USE OF HIGH-QUALITY STANDARDS SUCH AS USP'S TO ENSURE THE QUALITY OF MEDICINES, FOOD INGREDIENTS, AND RELATED PRODUCTS. USP DISSEMINATES ITS STANDARDS TO PHARMACEUTICAL MANUFACTURERS, PHARMACISTS, FOOD MANUFACTURERS, AND OTHER USERS THROUGH ITS USP-NF, FOOD CHEMICALS CODEX (FCC), OTHER COMPENDIA AND PUBLICATIONS, AND OFFICIAL USP REFERENCE STANDARD MATERIALS. THESE STANDARDS ARE SHARED WITH OTHER COUNTRIES AROUND THE WORLD VIA THEIR DRUG REGULATORY AGENCIES AND COMPANIES. INCREASINGLY, DRUG REGULATORY AUTHORITIES IN OTHER COUNTRIES ARE RECEIVING ASSISTANCE FROM USP IN UNDERSTANDING HOW THEY CAN IMPROVE THE QUALITY OF MEDICINES PROVIDED TO THEIR CITIZENS BY USING USP STANDARDS. VOLUNTEER EXPERTS FROM THOSE COUNTRIES ARE ACTIVE PARTICIPANTS IN USP'S STANDARDS-SETTING BODIES. IN ADDITION, USP DEVELOPS STANDARDS THAT ARE VITAL TO ENSURING AND IMPROVING PATIENT SAFETY IN A VARIETY OF SETTINGS RELATED TO THE APPROPRIATE LABELING, STORAGE, DISTRIBUTION AND USE OF MEDICINES. HEALTH CARE CLINICIANS AS WELL AS PATIENTS RELY ON THESE STANDARDS TO HELP ENSURE THAT MEDICINES ARE DELIVERED AND USED APPROPRIATELY. FORM 990, PART III, LINE 4B: PROGRAM SERVICE ACCOMPLISHMENTS ALLIED COMPENDIAL PROGRAMS - USP CONDUCTS VERIFICATION PROGRAMS FOR PHARMACEUTICAL INGREDIENTS, AND FOR DIETARY SUPPLEMENT INGREDIENTS AND PRODUCTS. THESE PROGRAMS INVOLVE INDEPENDENT TESTING AND REVIEW TO VERIFY THE IDENTITY, STRENGTH, QUALITY AND PURITY OF INGREDIENTS AND PRODUCTS FOR MANUFACTURERS WHO CHOOSE TO PARTICIPATE. THEY HELP TO IMPROVE THE QUALITY OF MEDICINES AND DIETARY SUPPLEMENTS THAT ARE MANUFACTURED AND THEN PROVIDED TO PATIENTS AND CONSUMERS THROUGH THE GLOBAL SUPPLY CHAIN. USP CONDUCTS EDUCATIONAL CLASSES AND PROGRAMS FOR CHEMISTS, SCIENTISTS, AND HEALTHCARE PRACTITIONERS IN THE UNITED STATES AND AROUND THE WORLD. USP SEEKS TO IMPROVE THE EFFECTIVE USE OF ITS STANDARDS THAT AFFECT BEST PRACTICES IN MANUFACTURING AND REGULATION OF PHARMACEUTICALS, DIETARY SUPPLEMENTS, AND FOOD INGREDIENTS. FORM 990, PART III, LINE 4C: PROGRAM SERVICE ACCOMPLISHMENTS NON-COMPENDIAL - USP'S GLOBAL HEALTH DIVISION CONTRIBUTES TO IMPROVED GLOBAL HEALTH BY ENSURING THE AVAILABILITY OF RELEVANT PUBLIC STANDARDS FOR THE WORLD'S MOST ESSENTIAL MEDICINES, SUPPORTING THE GLOBAL MANUFACTURING SECTOR TO INCREASE THE SUPPLY OF QUALITY ASSURED MEDICINES, AND STRENGTHENING NATIONAL AND REGIONAL REGULATORY SYSTEMS TO SUPPORT IMPROVED QUALITY ASSURANCE SYSTEMS, GLOBALLY. USP IMPLEMENTS ITS PROMOTING THE QUALITY OF MEDICINES (PQM PLUS) PROGRAM IN COOPERATION WITH USAID, TO HELP THE QUALITY OF MEDICINES IN MORE THAN 30 COUNTRIES AROUND THE WORLD. THROUGH OUR ADVANCED TRAINING AND LABORATORY FACILITY IN GHANA, USP SUPPORTS WORKFORCE DEVELOPMENT IN AFRICA TO SUPPORT CONTINUED IMPROVEMENT OF PHARMACEUTICAL QUALITY ASSURANCE AND QUALITY CONTROL EFFORTS IN THE REGION. USP MAINTAINS FOUR REGIONAL NETWORKS OF OFFICIAL MEDICINES CONTROL LABORATORIES (NOMCOL) WHICH HELP BUILD REGIONAL COOPERATION AND SUSTAINABLE CAPACITY FOR ONGOING EFFORTS TO ASSURE THE QUALITY OF MEDICINES, GLOBALLY. USP STANDARDS ARE MADE AVAILABLE TO REGULATORS IN LOWER AND MIDDLE INCOME COUNTRIES AT NO COST, OR AT SHARPLY DISCOUNTED COST. IN ADDITION, USP PROVIDES DIRECT TECHNICAL ASSISTANCE THROUGH A NUMBER OF OTHER GLOBAL HEALTH IMPACT PROGRAMS. USP ENGAGES IN OTHER PUBLIC HEALTH INITIATIVES INCLUDING SERVING AS THE SECRETARIAT FOR A MAJOR GROUP OF OTHER NON-PROFIT ORGANIZATIONS THAT JOIN TO COORDINATE PATIENT SAFETY/MEDICAL ERROR EFFORTS. UNDER FEDERAL LAW, ONE OF USP'S HEALTH CARE INFORMATION INITIATIVES IS THE DEVELOPMENT OF A DRUG CLASSIFICATION SYSTEM THAT MEDICARE PRESCRIPTION DRUG BENEFIT PLANS MAY USE TO DEVELOP THEIR FORMULARIES. FORM 990, PART VI, SECTION A, LINE 6 MEMBERS OR STOCKHOLDERS THE MEMBERS OF THE USP CONVENTION ARE REPRESENTATIVES FROM ORGANIZATIONS IN THE US AND ABROAD IN THE FOLLOWING CATEGORIES: - HEALTH PRACTITIONER PROFESSIONAL AND SCIENTIFIC ASSOCIATIONS - CONSUMER AND OTHER PUBLIC INTEREST ORGANIZATIONS - MANUFACTURER, TRADE, AND AFFILIATED ASSOCIATIONS - GOVERNMENTAL BODIES, DIVISIONS, OR ASSOCIATIONS - NON-GOVERNMENT STANDARDS-SETTING AND CONFORMITY ASSESSMENT BODIES FORM 990, PART VI, SECTION A, LINE 7A MEMBERS OR STOCKHOLDERS WHO MAY ELECT AND DECISIONS SUBJECT TO APPROVAL THE MEMBERS OF USP ELECT THE MEMBERS OF THE BOARD OF TRUSTEES AT EACH FIVE-YEAR MEETING OF THE CONVENTION. UP TO THREE ADDITIONAL TRUSTEES MAY BE APPOINTED BY THE BOARD DURING THE FIVE-YEAR CYCLE. GOVERNANCE DECISIONS OF THE ORGANIZATION RESERVED TO MEMBERS INCLUDE ELECTING THE BOARD OF TRUSTEES (BOT) AND THE COUNCIL OF EXPERTS (COE) AS WELL AS AMENDING BYLAWS AND ADOPTING RESOLUTIONS. FORM 990, PART VI, SECTION A, LINE 7B SEE EXPLANATION FOR FORM 990, PART VI, LINE 7A FORM 990, PART VI, SECTION B, LINE 11B FORM 990 REVIEW PROCESS THE FORM 990 WAS REVIEWED BY THE CHIEF FINANCIAL OFFICER AND PRESENTED TO CURRENT USP OFFICERS AS WELL AS THE AUDIT COMMITTEE AND APPROVED BY THE FULL BOARD PRIOR TO FILING WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C CONFLICT OF INTEREST POLICY MONITORING & ENFORCEMENT USP'S CONFLICT OF INTEREST POLICY IS REFLECTED IN ITS BYLAWS AND IN ITS CODE OF ETHICS. THIS POLICY IS IMPLEMENTED WITH RESPECT TO OUR EMPLOYEES AND VOLUNTEERS (MEMBERS OF THE BOARD OF TRUSTEES AND THE COUNCIL OF EXPERTS AND EXPERT COMMITTEES, USP'S STANDARD SETTING BODIES) THROUGH SPECIFIC PROVISIONS IN THE EMPLOYEE HANDBOOK, THE RULES OF BUSINESS PRACTICE FOR THE BOARD OF TRUSTEES, AND THE RULES AND PROCEDURES OF THE COUNCIL OF EXPERTS. ALL TRUSTEES, MEMBERS OF THE COUNCIL OF EXPERTS AND EXPERT COMMITTEES, AND EMPLOYEES IN DIRECTOR LEVEL OR ABOVE POSITIONS OR POSITIONS WHERE THEY WORK WITH EXPERT COMMITTEES OR OTHER EXTERNAL STAKEHOLDERS (INCLUDING STAFF WHO FREQUENTLY INTERACT WITH CUSTOMERS AND OTHER THIRD PARTIES) ARE REQUIRED TO SUBMIT AND KEEP CURRENT A DISCLOSURE STATEMENT IDENTIFYING ANY CONFLICT OF INTEREST. FOR USP'S VOLUNTEERS, A CONFLICT OF INTEREST IS DEFINED BROADLY UNDER THE BYLAWS TO INCLUDE A FINANCIAL INTEREST IN A COMPANY OR ANY OTHER RELATIONSHIP OR INTEREST THAT COULD INTERFERE WITH THE INDIVIDUAL'S ABILITY TO EXERCISE INDEPENDENT JUDGMENT. TRUSTEES, EXPERTS AND EMPLOYEES ARE REQUIRED TO RECUSE THEMSELVES FROM ANY MATTER IN WHICH THEY HAVE A POTENTIAL CONFLICT, AND EMPLOYEES MAY ALSO BE REQUIRED TO DIVEST THEMSELVES OF INTERESTS THAT PRESENT A POTENTIAL CONFLICT. AT EACH MEETING OF THE BOARD AND ALL EXPERT COMMITTEES, THE CHAIR REMINDS MEMBER OF THE CONFLICT OF INTEREST RULES. THE IDENTIFICATION AND RESOLUTION OF CONFLICTS OF INTEREST IS HANDLED AS FOLLOWS FOR USP EMPLOYEES AND VOLUNTEERS: EMPLOYEES: DISCLOSURE STATEMENTS ARE COLLECTED ANNUALLY BY THE GLOBAL COMPLIANCE AND ETHICS DEPARTMENT FROM EMPLOYEES AT THE DIRECTOR LEVEL AND ABOVE OR WHO OTHERWISE HOLDS A POSITION IN WHICH THE EMPLOYEE ACTIVELY PARTICIPATES IN THE STANDARDS-SETTING PROCESS. IF AN EMPLOYEE DISCLOSES THAT HE OR SHE HAS A FINANCIAL INTEREST ABOVE THE SPECIFIED THRESHOLD, THE VICE PRESIDENT, GLOBAL COMPLIANCE AND ETHICS REVIEWS THE INTEREST WITH THE CEO. IF THE CEO DETERMINES THAT THE INTEREST IS AN ISOLATED ONE AND ONE THAT WOULD BE DIFFICULT TO DIVEST (E.G., A RETIREMENT PLAN FROM A FORMER EMPLOYER, OR A SPOUSE'S EMPLOYMENT), THE EMPLOYEE IS ALLOWED TO RETAIN THE INTEREST BUT MUST RECUSE HIMSELF/HERSELF IN ANY SITUATION WHERE THERE IS A POTENTIAL CONFLICT. IN OTHER CASES, SUCH AS WHERE THERE ARE MULTIPLE INTERESTS ABOVE THE THRESHOLD, THE CEO MAY ASK THE EMPLOYEE TO DIVEST. MEMBERS OF THE BOARD OF TRUSTEES: DISCLOSURE STATEMENTS ARE COLLECTED BY THE SECRETARY, AND THE BOARD MEMBERS HAVE AN OBLIGATION TO UPDATE THEM AS NECESSARY TO KEEP THEM CURRENT. IF A BOARD MEMBER HAS A POTENTIAL CONFLICT, THEN IN ACCORDANCE WITH THE BYLAWS HE OR SHE MUST RECUSE HIMSELF/HERSELF FROM ANY FINAL DELIBERATION AND VOTE IN THE MATTER. COUNCIL OF EXPERTS AND EXPERT COMMITTEE MEMBERS: DISCLOSURE STATEMENTS ARE COLLECTED BY THE EXECUTIVE SECRETARIAT, AND MEMBERS HAVE AN OBLIGATION TO UPDATE THEM AS NECESSARY TO KEEP THEM CURRENT. THE CHAIR OF EACH EXPERT COMMITTEE, WORKING WITH STAFF (SCIENTIFIC LIAISON/EXECUTIVE SECRETARIAT), HAS RESPONSIBILITY FOR RESOLVING CONFLICT ISSUES. FORM 990, PART VI, SECTION B, LINE 15 PROCESS FOR DETERMINING COMPENSATION THE USP BOARD OF TRUSTEES APPROVED A TOTAL COMPENSATION PHILOSOPHY WITH THE FOLLOWING KEY PROVISIONS: 1. USP WILL LINK BASE PAY AND VARIABLE PAY TO PERFORMANCE IN SUCH A WAY THAT IT ALIGNS WITH USP'S STRATEGIC PLANNING PROCESS AND OUTCOME-BASED METRICS, AND RESULTS IN DIFFERENTIAL REWARDS. 2. USP WILL CONTINUALLY EVALUATE AND REALIGN PERFORMANCE MEASURES TO CONFORM TO CHANGING STRATEGIC GOALS AND OTHER BUSINESS NEEDS. 3. USP'S TOTAL CASH COMPENSATION PROGRAM WILL BE DESIGNED USING A MARKET-DRIVEN WHOLE JOB FAMILY STRUCTURE TO DELIVER ABOVE AVERAGE TOTAL COMPENSATION, DIRECT AND INDIRECT, RELATIVE TO THOSE OFFERED WITHIN VARIOUS LABOR MARKETS IN WHICH USP COMPETES FOR TALENT. THE TOTAL COMPENSATION PACKAGE WILL BE ESTABLISHED, REVIEWED, AND APPROVED IN A MANNER THAT QUALIFIES FOR THE REBUTTABLE PRESUMPTION OF REASONABLENESS AND WILL BE REVIEWED PERIODICALLY TO ENSURE THAT IT CONTINUES TO BE ALIGNED WITH USP'S STRATEGIC DIRECTION AND FINANCIAL LIMITS AND CONTINUES TO BE BOTH REASONABLE AND COMPETITIVE. UNDER THE RULES OF BUSINESS PRACTICE OF THE BOARD OF TRUSTEES IS RESPONSIBLE FOR OVERSEEING THE ORGANIZATION'S COMPENSATION AND BENEFITS SYSTEMS AND PROGRAMS, INCLUDING: - REVIEWING AND MAKING RECOMMENDATIONS TO THE BOARD REGARDING THE OVERALL COMPENSATION PHILOSOPHY AND PRINCIPLES OF THE ORGANIZATION. - REVIEWING THE STRUCTURE OF THE STAFF COMPENSATION PROGRAM, INCLUDING SALARY LEVELS, BENEFITS, AND THE SUCCESS SHARING PLAN AND THE EXTENT TO WHICH THEY ARE ACHIEVING DESIRED PURPOSES. - REVIEWING AND MAKING RECOMMENDATIONS TO THE EXECUTIVE COMMITTEE AND THE BOARD REGARDING EMPLOYEE BENEFIT PLANS AND EMPLOYEE BENEFITS, WITH THE BOARD RETAINING RESPONSIBILITY FOR FINAL APPROVAL OF THE INSURER OR INSURERS THROUGH WHOSE POLICIES THE PLAN BENEFITS ARE TO BE FUNDED AND THE RULES AND PROCEDURES FOR ADMINISTRATION OF THE PLAN. - BASED ON INPUT FROM THE CEO REVIEWING AND MAKING RECOMMENDATIONS TO THE BOARD REGARDING THE PROPOSED METRICS FOR ORGANIZATIONAL PERFORMANCE UNDER THE SUCCESS SHARING PLAN, AND THE ACHIEVEMENT OF SUCH METRICS. FORM 990, PART VI, SECTION C, LINE 19 HOW DOCUMENTS ARE MADE AVAILABLE TO THE PUBLIC USP MAKES THESE DOCUMENTS AVAILABLE TO THE PUBLIC TO THE EXTENT REQUIRED BY LAW AND UPON REQUEST. FORM 990, PART IX, LINE 11G PROFESSIONAL SERVICES: PROGRAM SERVICE EXPENSES 15,252,658. MANAGEMENT AND GENERAL EXPENSES 8,079,972. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 23,332,630. CONSULTING: PROGRAM SERVICE EXPENSES 7,437,172. MANAGEMENT AND GENERAL EXPENSES 3,140,276. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 10,577,448. RECRUITMENT: PROGRAM SERVICE EXPENSES 293,110. MANAGEMENT AND GENERAL EXPENSES 1,012,583. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 1,305,693. TRAINING: PROGRAM SERVICE EXPENSES 123,244. MANAGEMENT AND GENERAL EXPENSES 44,330. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 167,574. FORM 990, PART XI, LINE 9: INTERCOMPANY INVESTMENT ELIMINATIONS - RECLASS UNREALIZED GAIN ON FOREIGN EXCHANGE 113,858. ELIMINATIONS OF INTERCOMPANY PAYABLES -2,354,232. INTERCOMPANY ELIMINATION ADJUSTMENT -119,423. USP HOLDING LLC 12601 TWINBROOK PARKWAY ROCKVILLE MD 20852 562515663 HOLDING MD 30808569 17148348 USP USP HOLDING INTERNATIONAL LLC 12601 TWINBROOK PARKWAY ROCKVILLE MD 20852 562515662 HOLDING MD 0 0 USP UNITED STATES PHARMACOPEIA - GHANA NO3 PARK AVE MOTORWAY EXTN ACCRA GH WY 1204 131656692 PHARMACEUTICAL TRAINING GH FOREIGN USP HOLDING 1 US PHARMACOPEIA NIGERIA LTDGTE 2 CONNAL ROAD LAGOS NI SCIENTIFIC NI USPC C 1314433 1579127 1.00000 1 US PHARMACOPEIA PHILIPPINES INC 3/F MIDWAY COURT EDSA WACK WACK MANILA RP SCIENTIFIC RP USPC C 215985 1.00000 1 UNITED STATES FARMACOPEIA BRASIL LTDA WTORRE TECHNOLOGY PARK AVENIDA CECI SAO PAULO BR N 1 131656692 SCIENTIFIC BR USPHUSPHI C 2218698 3312253 1.00000 1 US PHARMACOPEIA STND RESEARCH & DEV WAIGAOQIAO FREE TRADE 520 NFU TE SHANGHAI CH 200131 131656692 SCIENTIFIC CH USP HOLDING C 3829518 2875041 1.00000 1 US PHARMACOPEIA INDIA PRIVATE LTD ICICI KNOWLEDGE PARK GENOME VALLEY HYDERBAD IN 500 131656692 SCIENTIFIC IN USPHUSPHI C 16451402 19020626 1.00000 1 US PHARMACOPEIA-SINGAPORE PTELTD 37TH FL SING 50 RAFFLES PLACE STE SINGAPORE SN 048623 131656692 SCIENTIFIC SN USP HOLDING C 1204863 1230327 1.00000 1 US PHARMACOPEIA SWITZERLAND AG MUNCHENSTEINERSTRASSE 41 BASEL SZ 4052 131656692 SCIENTIFIC SZ USP HOLDING C 2914960 4050850 1.00000 1 USP KENYA OFFICE NO 8 MUGUMO GARDENS 90 JA NAIROBI LAVINGTON KE 131656692 SCIENTIFIC KE USP HOLDING C 829334 339543 1.00000 1 PHARMATECH ASSOCIATES INC 22320 FOOTHILL BLVD SUITE 330 HAYWARD CA 94541 943347981 SCIENTIFIC CA USP HOLDING C 6560545 1283841 1.00000 1 0 0 0 1 0 1 0 0 0 0 0 0 1 0 0 0 1 0 1 PHARMATECH ASSOCIATES INC D 4000000 FMV UNITED STATES FARMACOPEIA BRASIL LTDA F 668217 FMV US PHARMACOPEIA INDIA PRIVATE LTD F 902069 FMV PHARMATECH ASSOCIATES INC M 90097 FMV US PHARMACOPEIA-SINGAPORE PTELTD M 1029268 FMV US PHARMACOPEIA STND RESEARCH & DEV M 356208 FMV US PHARMACOPEIA INDIA PRIVATE LTD M 3418679 FMV UNITED STATES PHARMACOPEIA - GHANA M 283479 FMV USP KENYA M 219073 FMV UNITED STATES FARMACOPEIA BRASIL LTDA M 172391 FMV US PHARMACOPEIA SWITZERLAND AG M 3530328 FMV US PHARMACOPEIA INDIA PRIVATE LTD Q 99076 FMV UNITED STATES PHARMACOPEIA - GHANA Q 225070 FMV USP KENYA Q 452167 FMV US PHARMACOPEIA SWITZERLAND AG Q 2314505 FMV UNITED STATES PHARMACOPEIA - GHANA S 200000 FMV US PHARMACOPEIA SWITZERLAND AG S 101667 FMV US PHARMACOPEIA-SINGAPORE PTELTD S 837993 FMV US PHARMACOPEIA INDIA PRIVATE LTD S 6460904 FMV PHARMATECH ASSOCIATES INC S 6910620 FMV UNITED STATES PHARMACOPEIA - GHANA S 12280000 FMV US PHARMACOPEIA STND RESEARCH & DEV S 12320000 FMV UNITED STATES FARMACOPEIA BRASIL LTDA S 595664 FMV US PHARMACOPEIA STND RESEARCH & DEV S 15400000 FMV